- Home
- REE vs LNAI Comparison
REE vs LNAI Comparison
Compare REE & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- LNAI
- Stock Information
- Founded
- REE 2011
- LNAI N/A
- Country
- REE Israel
- LNAI United States
- Employees
- REE N/A
- LNAI N/A
- Industry
- REE Auto Manufacturing
- LNAI Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- LNAI Health Care
- Exchange
- REE Nasdaq
- LNAI Nasdaq
- Market Cap
- REE 22.4M
- LNAI 22.3M
- IPO Year
- REE N/A
- LNAI N/A
- Fundamental
- Price
- REE $0.86
- LNAI $1.04
- Analyst Decision
- REE Strong Buy
- LNAI
- Analyst Count
- REE 2
- LNAI 0
- Target Price
- REE $11.75
- LNAI N/A
- AVG Volume (30 Days)
- REE 1.1M
- LNAI 8.7M
- Earning Date
- REE 12-16-2025
- LNAI 10-03-2025
- Dividend Yield
- REE N/A
- LNAI N/A
- EPS Growth
- REE N/A
- LNAI N/A
- EPS
- REE N/A
- LNAI N/A
- Revenue
- REE $183,000.00
- LNAI N/A
- Revenue This Year
- REE $327.73
- LNAI N/A
- Revenue Next Year
- REE $36,888.82
- LNAI N/A
- P/E Ratio
- REE N/A
- LNAI N/A
- Revenue Growth
- REE N/A
- LNAI N/A
- 52 Week Low
- REE $0.53
- LNAI $0.81
- 52 Week High
- REE $11.72
- LNAI $21.00
- Technical
- Relative Strength Index (RSI)
- REE 39.10
- LNAI N/A
- Support Level
- REE $1.06
- LNAI N/A
- Resistance Level
- REE $1.10
- LNAI N/A
- Average True Range (ATR)
- REE 0.12
- LNAI 0.00
- MACD
- REE -0.05
- LNAI 0.00
- Stochastic Oscillator
- REE 0.03
- LNAI 0.00
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About LNAI Lunai Bioworks Inc. Common Stock
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.